1. EZH2 inhibitors sensitize myeloma cell lines to panobinostat resulting in unique combinatorial transcriptomic changes
   Taylor Harding et al, 2018, Oncotarget CrossRef
2. Perturbing Enhancer Activity in Cancer Therapy
   Feda H. Hamdan et al, 2019, Cancers CrossRef
3. Epigenetics of Triple-Negative Breast Cancer via Natural Compounds
   Mohammed Kaleem et al, 2022, Current Medicinal Chemistry CrossRef
4. Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells
   Annalisa Romanelli et al, 2020, ACS Medicinal Chemistry Letters CrossRef
5. Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects
   Lilin Wan et al, 2022, Frontiers in Immunology CrossRef
6. Epigenetics of Most Aggressive Solid Tumors: Pathways, Targets and Treatments
   Javier Martinez-Useros et al, 2021, Cancers CrossRef
7. Epigenetic Targeting of Aberrant Transcriptional Modulation in Pancreatic Cancer
   Feda Hamdan et al, 2018, Epigenomes CrossRef
8. The role of H3K27me3 methylation in cancer development
   Longjiang Di et al, 2024, Genome Instability & Disease CrossRef